Background: Serum protein profiling patterns can reflect the pathological state of a patient and therefore may be useful for clinical diagnostics. Here, we present results from a pilot study of proteomic expression patterns in hemodialysis patients designed to evaluate the range of serum proteomic alterations in this population. Methods: Surface-enhanced laser desorption/ionization timeof-flight mass spectrometry (SELDI-TOF-MS) was used to analyze serum obtained from patients on periodic hemodialysis treatment and healthy controls. Serum samples from patients and controls were first fractionated into six eluants on a strong anion exchange column, followed by application to four array chemistries representing cation exchange, anion exchange, metal affinity and hydrophobic surfaces. A total of 144 SELDI-TOF-MS spectra were obtained from each serum sample. Results: The overall profiles of the patient and control samples were consistent and reproducible. However, 30 welldefined protein differences were observed; 15 proteins were elevated and 15 were decreased in patients compared to controls. Serum from 1 patient exhibited novel protein peaks suggesting possible additional changes due to a secondary disease process. Conclusion:SELDI-TOF-MS demonstrated consistent serum protein profile differences between patients and controls. Similarity in protein profiles among dialysis patients suggests that patient physiological responses to end-stage renal disease and/or dialysis therapy have a major effect on serum protein profiles.
Introduction
Proteomics can be defined as the characterization of total protein composition of an organism [1] . Comparative proteomic analysis under different physiological states may be a powerful approach for identifying biomarkers of health status, since many proteins that are secreted into bodily fluids are differentially expressed in response to physiological changes such as infection or inflammation. Identification of proteins characteristic of a specific disease may provide biomarkers that can be used in simple, non-invasive clinical diagnostics [2] [3] [4] .
One approach to identify differentially expressed proteins is surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). SEL-DI-TOF-MS is an array-based MS technology introduced by Hutchens and Yip [5] that utilizes selective adsorption of a subset of proteins in a given sample to array surfaces differing in chemical coating [6] . Arrays are functionalized for ion exchange, immobilized metal affinity, or hydrophobic selectivity allowing the serum sample to be fractionated into subsets of proteins with similar chemical affinity. Proteins captured on the array are ionized, and their masses are determined by time-of-flight (TOF) MS. A principle advantage of SELDI-TOF-MS is the ability to rapidly screen hundreds to thousands of proteins for differences between diseased individuals and control subjects, even if the protein functions and identities are unknown. Thus, this technique provides a broad unbiased screen for protein expression differences. Once a candidate protein is detected, however, additional experimental work is required to determine the identity and function of the candidate biomarker.
To date, the SELDI-TOF-MS technique has primarily been used to screen for candidate biomarkers for specific diseases. This approach has yielded potential biomarkers for prostate, bladder, lung, breast and ovarian cancers as well as Alzheimer's disease [7] [8] [9] [10] [11] [12] . In addition, we believe that this approach has considerable potential for monitoring patients with complex chronic conditions or syndromes to identify episodes of relapse, infection, or drug failure. There is one report, for example, of the analysis of urine protein profiles to characterize renal allograft rejection [13] . Analysis of patients with chronic conditions, however, is complicated by protein profile alterations due to the underlying condition and potential patient-topatient variability in disease state. The ability to rapidly screen large numbers of protein types per patient provides a detailed protein profile facilitating interpretation of these complex factors [14, 15] . Consequently, the present pilot study was designed to compare serum samples from hemodialysis patients with samples from healthy controls to investigate the effects of end-stage renal disease on serum protein profiles. In the future, it is hoped that protein profiles may help to identify infections or other complications in dialysis patients [16] .
Before SELDI-TOF-MS can be applied to studies of complications in dialysis patients, it is important to understand the effects of end-stage renal disease and dialysis treatments on serum protein profiles. Kidney failure can be caused by a variety of underlying complications including diabetes, hypertension, and glomerulonephritis, and each of these etiologies could have a different effect on serum components. The dialysis process itself alters the concentrations of low-vs. high-molecular-weight proteins in serum depending on the time of sampling. Protein profiles could also be altered by patient responses to the hemodialysis process (e.g. inflammation, cytokine production). Finally, patient-to-patient variation in the presence of other chronic diseases or health complications may be important. While there is a growing literature characterizing specific serum proteins and metabolites in hemodialysis patients [17] [18] [19] [20] , the focus of this study is to begin to evaluate a broad profile of serum proteins in patients vs. control individuals in order to understand the effects of the complexities described above. A better understanding of these issues would facilitate future application of protein profiles to the diagnosis of complications in dialysis patients.
Materials and Methods
Protocols for this study were reviewed and approved by the LLNL Institutional Review Board and comply with NIH guidelines. Blood samples were obtained with informed consent from 4 unaffected healthy control subjects, and 4 patients that are receiving dialysis treatments three times per week as a consequence of renal failure. Samples from dialysis patients were obtained prior to their routine dialysis session. The 4 dialysis patients (subjects 1-4) consisted of 3 females and 1 male between the ages of 29 and 63 years. Causes of renal failure differed for each of these 4 patients. End-stage renal disease was secondary to the following causes: diabetes, cyclosporine toxicity, IgA nephropathy, and hypertension. The 4 control subjects (subjects 5-8) consisted of 2 females and 2 males, with an age range of 32-52 years. Blood from all subjects were collected in 2.5 ml BD vacutainer SST glass serum tubes (Becton Dickinson, Franklin Lakes, N.J., USA) and spun at 2,500 rpm at 4°C for 30 min. The separated serum was divided into 0.1-ml aliquots and stored at -80°C until analysis. All samples were coded before sample preparation and MS analysis. SELDI-TOF-MS analysis was performed blindly with no knowledge of the source of the samples. After the experimental work was completed, results were identified as coming from patient or control group samples to compare protein profiles between groups.
Frozen serum samples were prepared for SELDI-TOF-MS as outlined in figure 1. Each serum sample (subjects 1-8) was thawed and spun at 20,000 g for 10 min at 4°C. 30 Ìl of pH 9.0 buffer (9 M urea/2% CHAPS/50 mM Tris-HCl) was added to 20 Ìl of each serum sample before mixing with Q Ceramic HyperD ® F beads (Ciphergen Biosystems, Fremont, Calif., USA) in a filtration plate. Proteins were eluted through the filter by washes with buffers of different pH. [21] . The energy-absorbing molecules (EAMs), ·-cyano-4-hydroxy cinnamic acid (CHCA) and sinapinic acid (SPA) were deposited on the array spots and allowed to air dry. Different EAMs and laser powers were used to optimize detection for proteins differing in molecular weight (MW). CHCA was used as the EAM for proteins with a MW ! 15 kDa, while SPA was used primarily for proteins with MW 1 15 kDa. These fractionations provide a broad coverage of proteins based on chemical class rather than function. A total of 144 TOF mass spectra analyzing proteins with mass to charge ratio (m/z) from 1 to 200 kDa were obtained for each sample (reflecting 72 different conditions in duplicate). For SELDI-TOF-MS, proteins and peptides were detected using a Ciphergen PBS-IIC ProteinChip ® Reader, a time-lag focusing, linear, laser desorption/ionization TOF-MS. All spectra were acquired in the positive-ion mode. Each spectrum was an average of 130 laser shots and externally calibrated against a mixture of known peptides or proteins. The spectra were analyzed using the Biomarker Wizard function in ProteinChip ® Software v3.1.1.
Results and Discussion
Overall, the 8 serum samples yielded qualitatively similar protein profiles with the 72 different fractionation and ProteinChip ® Array conditions. The data in figure 2a show a typical example with the major peaks very consistent among all dialysis patients and all controls, with a few minor peaks varying between individuals. It is difficult to quantify the total number of protein features analyzed from each sample because some features appear in multiple array conditions, and some minor features are hard to differentiate from noise. Experience with previous studies and literature reports provide an estimate that about 500-1,000 protein features per sample are detected in a study of this size [15] .
A number of clearly defined peaks were observed that consistently distinguish the patient samples (1-4) from the control samples (5-8) across the 72 analysis conditions. Two spectra were chosen to illustrate differences between patients and controls. The spectra in figure 2b show peaks at 5.8 and 11.7 kDa that have greater intensity in all patients compared with controls, while peaks at 7.7 and 9.3 kDa have reduced intensity in patients compared with controls. A close-up view from another fraction and EAM shows two of these peaks at 9.3 and 11.7 kDa that consistently distinguish patients from controls ( fig. 2c) . The majority of peaks, however, show similar amplitudes among all samples.
A listing of protein peaks that differ between patients and controls is shown in table 1. A total of 15 candidate proteins showed increased intensity in at least 3 out of 4 patients compared with all controls, while 15 candidates showed decreased intensity in at least 3 out of 4 patients compared with all controls. For 60% of these candidate protein peaks, intensities for all 4 patients were outside the range for all 4 controls. Thus, most candidate proteins clearly distinguish all patients from all controls in this study. A few samples are listed as outliers in table 1 as they lacked, or in some cases contained, one or more peaks that were characteristic of their group. In addition, data from subject 4 showed two strong peaks at 15.2 and 15.9 kDa that were not present in any of the other 7 samples ( fig. 2c) , suggesting that another factor besides dialysis may be responsible for these peaks.
Unfortunately, substantial additional biochemical analysis is required to determine the identity of each of these 30 candidate proteins. It may ultimately be possible to correlate the profile of protein differences with disease status without peak identification. Our hope, however, is that with further studies of patients and controls, we can focus on a smaller number of diagnostic peaks for identification that may contribute to a better understanding of end-stage renal disease.
The results of this SELDI-TOF-MS study provide an overview of serum protein profile alterations in hemodialysis patients. While it is difficult to quantify the exact frequency of protein alterations, our observation of 30 candidate protein biomarkers that distinguish the two populations is much larger than the 1-5 candidate markers reported from similar studies on specific diseases [9, 12, 13, 22, 23] . Thus, dialysis treatment, or clinical factors present in end-stage renal disease, have a dramatic effect Note: Fraction, Chip surface, and EAM/laser intensity indicate the experimental conditions used where the candidate peak was observed. Multiple entries (e.g. 9.3 kDa) indicate that the candidate peak was observed using several experimental conditions. on serum protein profiles. The 4 dialysis patients share most of these 30 protein alterations, and more than half of the marker changes are shared by all patients compared with all controls. This suggests that renal failure in general, or dialysis therapy, both of which are shared by all patients, may have a greater effect on protein profile alterations than the underlying causes of kidney failure that differed among all 4 patients.
A dialysis treatment effect could result from either differential loss of low MW components through the dialysis membrane, or from patient responses to dialysis such as the production of cytokines or inflammatory response proteins. The data in table 1 show that biomarker proteins vary in MW from 1.9 to 78.8 kDa, and that the biomarkers elevated in patients were spread across the full MW range. This suggests that patient physiological responses to dialysis are more important than dialysis membrane fractionation in producing the observed protein profile patterns. Finally, the unique protein markers observed in patient 4 suggest other clinical factors may be present in this individual in addition to end-stage kidney disease. One clinical factor that is unique to patient 4 is that this is the only subject with hepatitis C. Further studies would be required to determine if hepatitis or liver damage are the cause of differential protein markers seen in this patient.
In summary, SELDI-TOF-MS provides a convenient, rapid method for screening large numbers of serum proteins to characterize protein profile alterations in complex clinical conditions. This pilot study was designed to provide insights into the effects of end-stage renal disease and dialysis treatments on serum protein profiles. Our results show that although a number of factors in hemodialysis patients such as secondary diseases must be considered, SELDI-TOF-MS may be useful in the future as a diagnostic tool to identify treatment complications and potentially reduce patient mortality. Our results show that while patients differ dramatically from controls, the protein profiles of dialysis patients are similar to each other. This suggests that there may be characteristic profile for dialysis patients. The unique features in patient 4 support the potential of detecting additional clinical conditions. Future studies with larger numbers of dialysis patients and control individuals will be required to determine whether treatment-related complications could also be detected using this approach.
